RESTRUCTURING, DIVESTITURES, AND ASSET IMPAIRMENTS (Tables)

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Summary of Impairments and Divestiture Losses (Gains)

Stericycle recognized the following Divestiture losses (gains), net in the Consolidated Statements of (Loss) Income:

In millions
	Year Ended December 31, 2023
	Loss (gain) - pre-cumulative currency translation		Cumulative currency translation loss (gain) realized		Total loss (gain)
International Segment
Romania Operations	$	3.2	$	1.0	$	4.2
UAE Joint Venture	0.5		—		0.5
Netherlands Dental Operations	1.0		—		1.0
Republic of Korea Operations	(48.1)		(2.7)		(50.8)
Australia and Singapore Operations	5.1		2.2		7.3
Brazil Operations	26.1		70.1		96.2
International Container Manufacturing Operations	5.0		—		5.0
Divestiture losses (gains), net	$	(7.2)	$	70.6	$	63.4

Schedule of Impairments

Stericycle recognized the following asset impairment charges in the Consolidated Statements of (Loss) Income:

In millions
	Year Ended December 31,
	2023 (1)		2022 (2)		2021 (3)
North America
Asset Impairment - SG&A	$	—	$	5.5	$	2.1
Total North America Segment	$	—	$	5.5	$	2.1
International
Asset Impairment - COR	$	3.4	$	—	$	—
Asset Impairment - SG&A	3.1		—		4.6
Total International Segment	$	6.5	$	—	$	4.6

(1)The Company recognized an impairment in COR in International associated with certain long-lived assets, primarily property, plant and equipment in Romania and an impairment in SG&A in International associated with certain intangible assets in Spain.

(2)The Company recognized an impairment in SG&A in North America associated with exiting certain North America office facilities in the U.S.

(3)The Company recognized impairments in SG&A in North America associated with a Canada site exit and in International associated with certain customer relationship intangibles in Romania.